Global Burns Market Report to 2032 – Insight, Epidemiology and Forecasts – ResearchAndMarkets.com

Global Burns Market Report to 2032 – Insight, Epidemiology and Forecasts – ResearchAndMarkets.com




Global Burns Market Report to 2032 – Insight, Epidemiology and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Burns – Market Insight, Epidemiology and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

This report deliver an in-depth understanding of the Burns historical and forecasted epidemiology as well as the Burns market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Burns market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Burns market size from 2022 to 2032. The Report also covers current Burns treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Key Findings

  • In 2021, total incident population of burn injuries that required medical treatment in seven major markets were reported to be 1,864,208.
  • The number of hospitalized burn cases in the seven major market is expected to increase at an effective CAGR during the study period, i.e. 2019-2032.
  • The estimates suggest the United States had highest incident population of burn injuries that required medical treatment with 661,900 cases in 2021.
  • According to our analysis, after fire/flame (41%), scald was the foremost contributing cause for burn injuries in the US, occupying 31.4% of total incident cases of treatment taking burn injuries.
  • Our analysis indicates that the majority of burn injury cases taking treatment are males. This is accompanied by the fact that major burn injuries occur at workplaces; thus, the burn injury cases in males are predominantly higher. There were 410,378 male and 251,522 female cases of treated burn injuries in 2021, in the US.
  • In 2021, the severity-specific incident cases were 144,294; 386,550; 19,857; and 111,199 for first-degree, second-degree, third-degree, and unspecified, respectively in the United States.
  • According to our assessments for the United States, the estimated cases of hospitalized burn patients in 2021 were 76,383.
  • Among the EU5 countries, the UK had the highest incident population of burn patients that require medical treatment with 275,829 cases, followed by France (203,690 cases) and Spain (143,209 cases) in 2021. On the other hand, Italy had the lowest incident population (122,890).
  • Japan had 328,255 incident cases of burn injuries requiring medical treatment in 2021, the second-highest of all other countries in 7MM after the US.

Scope of the Report

  • The report covers the descriptive overview of Burns, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Burns epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Burns is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Burns market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Burns market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the Burns market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Burns R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Burns. The launch of emerging therapies will significantly impact the Burns market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Burns Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Burns Pipeline Analysis
  • Burns Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Burns Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Burns Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Burns Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving Burns.
  • To understand the future market competition in the Burns market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Burns in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Burns market.
  • To understand the future market competition in the Burns market.

Companies Mentioned

  • MediWound Germany GmbH
  • Kaken Pharmaceutical Co., Ltd.
  • Kerecis
  • Mallinckrodt Pharmaceuticals
  • Avita Medical
  • Vericel Corporation
  • KeraNetics
  • Integra LifeSciences Corporation
  • PolyNovo
  • Medline Industries
  • Anika Therapeutics, Inc.
  • ACell, Inc.
  • Amryt Pharma
  • CUTISS AG
  • Skingenix
  • RenovaCare

For more information about this report visit https://www.researchandmarkets.com/r/4196uf

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900